Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0ITBMZ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
HD-101
|
|||||
| Synonyms |
Amanitin-CD269 antibody drug conjugate; CD269-ATAC; anti-CD269-30.1699; anti-CD269-30.2115; anti-CD269-Thiomab-30.1699; anti-CD269-Thiomab-30.2115
Click to Show/Hide
|
|||||
| Organization |
Heidelberg Pharma AG
|
|||||
| Drug Status |
Clinical candidate
|
|||||
| Indication |
In total 1 Indication(s)
Multiple myeloma [ICD11:2A83]
Clinical candidate
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Linker Name |
Undisclosed
|
|||||
| TTD ID | ||||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.